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Preamble
During this last year, there has been much progress with regard to
anticoagulant and ablation therapy for atrial fibrillation (AF). Apart
from recently issued European Society of Cardiology Guidelines for
the management of patients with supraventricular arrhythmias, there
has been little progress in research in this field. Ventricular arrhyth-
mias and device therapy have seen modest progress.
Supraventricular tachycardias
This year has seen several publications on the ECG diagnosis of supra-
ventricular tachycardia (SVT)1–4 and interest in new consumer-led dis-
covery of supraventricular arrhythmias.5 EP mapping technology has
provided better mapping of SVT.6 There has been a surprising interest
in new antiarrhythmic drugs for SVT, ranging for intranasal etripamil
(an L-type calcium antagonist) for termination of SVT7,8 and nifekalant
to increase the refractoriness of accessory pathways and reduce the
rate of pre-excited supraventricular arrhythmias.9
Guidelines
2019 saw new European Society of Cardiology guidelines for the
management of patients with SVT10 which had previously been in
2003. However, there was little which was very new. The guidelines
insisted that ablation was the best initial management for most re-
entrant atrial and AV junctional tachycardia. However atrial tachycar-
dia occurring after ablation for AF should not be considered for abla-
tion until at least 3 months after the AF ablation procedure. The
guidelines stressed that ablation for AV nodal re-entrant tachycardia
could be achieved in almost all without risk of AV block. An invasive
EP risk assessment of Wolff–Parkinson–White syndrome was recom-
mended even in patients who are asymptomatic but have high-risk
occupations or are competitive athletes. The guidelines recommend
ablation in high risk or symptomatic WPW patients but stop short of
recommending ablation of all accessory pathways. It is pointed out
that SVT may cause tachycardia mediated cardiomyopathy and that
ablation may not only eliminate the tachycardia but restore ventricu-
lar function.
There are strong Class III recommendations—‘what not to do’,
mostly related to antiarrhythmic drug therapy (Figure 1).
Atrial fibrillation risk assessment
and treatment decisions
Various studies have highlighted new developments in the risk assess-
ment for the development of AF and its complications, as well as the
use of the non-vitamin K antagonist oral anticoagulants (NOACs) as
thromboprophylaxis.
Risk assessment
Numerous clinical factors associated with incident AF have been
described11 but a simple, practical and reliable approach to identifying
patients at risk of incident AF is needed.
Clinical factors such as change in body mass index have been asso-
ciated with an increased risk of AF,12 as has disordered sleep pat-
tern.13 Various clinical risk scores for identifying incident AF have
been described, and as with most clinical scores, all have modest pre-
dictive value for identifying high-risk patients and until recently, have
been complex models derived from multivariate analyses. The
C2HEST score was derived and validated in Asia and has recently
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.been externally validated in a French post-stroke cohort and the
Danish nationwide registries.14,15 This would facilitate targeted inten-
sive screening for AF, for example, in the post-stroke population with
AF, where oral anticoagulation (OAC) as secondary prevention is
well established. In contrast, two randomized trials in embolic stroke
of unknown source (ESUS) using NOACs failed to show a significant
reduction in recurrent stroke, while one trial (NAVIGATE-ESUS)
showed an excess of bleeds.16,17
Screening for AF has attracted much attention, with population-
based approaches and new technologies.18 The Apple Watch study
investigated if a smartwatch-based irregular pulse notification algorithm
identified possible AF, and reported that among participants who
received notification of an irregular pulse, 34% had atrial fibrillation AF
on subsequent ECG patch readings and 84% of notifications were con-
cordant with AF.19 The Huawei Heart Study also showed the usefulness
of photoplethysmographic (PPG) -based technology in population
screening for AF, with the positive predictive value of PPG signals being
91.6% and leading to improved anticoagulation use (>80%).20
Risk assessment continues to evolve, with availability of new data
showing stroke risks associated with AF patients with hypertrophic
cardiomyopathy21 and imaging-documented significant coronary artery
lesions.22 There has been much interest into use of sophisticated meth-
ods such as machine-learning, even predicting incident AF from a sim-
ple 12-lead ECG.23 More complex risk assessment approaches
improve AF stroke risk prediction (at least statistically) but need to be
balanced against simplicity and practical application. For now, an inde-
pendent Patient Cantered Outcome Research Institute (PCORI)-
sponsored systematic review and evidence appraisal identified that
amongst the commonly used risk stratification schemes in patients
with AF, the CHA2DS2VASc and HAS-BLED scores were the best
predictors for stroke and bleeding risks, respectively.24 Bleeding risk
prediction only focused on modifiable bleeding risk factors is an inferior
strategy to a formal risk assessment using the HAS-BLED score.25,26
Stroke and bleeding risk assessments incorporating biomarkers
have been proposed based on highly selected anticoagulated clinical
trial cohorts but ‘real-world’ studies have not shown the usefulness of
such schemes. One study showing sequential addition of biomarkers
did not improve the usefulness of stroke and bleeding risk predic-
tion.27 Also, there are no data across the patient pathway, when first
diagnosed and non-anticoagulated, or on aspirin—and following the
initiation of OAC. Of note, many risk factors are based on baseline
risk assessment but do not remain static and changes with age and in-
cident risk factors.25,28 Thus, AF assessment is not a ‘one off’ item and
needs to be reassessed at regular intervals, e.g. every 4–6 months.29
Non-vitamin K antagonist oral
anticoagulants and atrial fibrillation
management in clinical practice
The NOACs have changed the landscape of stroke prevention in AF.
These drugs are now the preferred OAC option in most guidelines,
but challenges remain in its use amongst high-risk subgroups that
were under-represented in clinical trials, as well as its adherence and
persistence.
Clinical trial cohorts are selected populations and may be at lower
risk compared to ‘real-world’ clinical practice data.30 The year also
saw the first publications of real-world data for edoxaban, which was
the fourth NOAC to enter the market.31 Increasing data for the
NOACs in the elderly have been published,32,33 clearly showing their
effectiveness and safety even in very elderly subjects, aged >_80.
Additional data emphasize the importance of using the appropriate
label-adherent dosing to ensure best outcomes, as well as persist-
ence data with the NOACs, for example, with dabigatran.34 One trial,
Figure 1 Some ‘What not to do’ recommendations from the 2019 ESC Guidelines on the management of patients with supraventricular tachycar-
dia. MRAT, macro re-entrant atrial tachycardia. Reproduced from Brugada et al.10
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..AEGEAN showed high adherence and persistence with apixaban
(90%) but did not show additional benefit from interventions to im-
prove adherence/persistence.35
Also, studies of NOAC use in extremes of renal function, both se-
vere renal impairment and supra-normal renal function. The latter is
pertinent given that all three Factor Xa inhibitors showed numerically
more ischaemic strokes in the subgroup with CrCl >95 mL/min when
compared with warfarin in their pivotal trials, although this is not ap-
parent in real-world observational data.36 In end-stage renal failure,
observational data show better safety for apixaban over warfarin.37
The last year has seen new trials with NOACs in catheter ablation
(CA) for AF, and in the setting of AF patients presenting with an ACS
or undergoing PCI/stenting. For CA, an uninterrupted NOAC-based
strategy appears to be a safer option compared to a warfarin-based
strategy.38–40 In AF/ACS/PCI patients, the publication to
AUGUSTUS and ENTRUST-AF PCI completes the trials of NOACs
in this clinical setting.41,42 These trials suggest that when OAC is
used, a NOAC-based regime or a dual therapy (i.e. OAC plus a
P2Y12 inhibitor) is associated with less major bleeding.43 Of the over-
all thrombotic or ischaemic outcomes, there is little difference be-
tween a triple therapy or dual therapy approach, or a NOAC-based
strategy compared to a warfarin-based strategy. However, a dual
therapy approach may be associated with an excess of stent throm-
bosis and myocardial ischaemic events, thus patients who are at high
risk of such outcomes may merit a short period of triple therapy at
the start. In stable coronary disease, OAC alone is associated with
better outcomes compared to dual therapy, in the AFIRE trial.44
While the concept of integrated AF management has been pro-
posed, its application and implementation in a simple user-friendly
manner have not been previously validated. Integrated care has been
associated with reduced mortality and hospitalization.46 One
integrated and holistic approach to AF management, streamlining the
decision-making management approaches that would be uniformly
applicable across the whole AF patient pathway, starting with primary
care and linking with secondary care (including cardiologist/non-car-
diologists), and understandable for the AF patients per se, is the ABC
(Atrial fibrillation Better Care) pathway: Avoid stroke; Better symp-
tom management with patient-centred symptom directed decisions
on rate or rhythm control; Cardiovascular and risk factor optimisa-
tion, including lifestyle changes45 (Figure 2). The ABC pathway ap-
proach has now been shown in independent studies to be associated
with a reduction in mortality, hospitalization and adverse outcomes,
as well as reduced healthcare costs, when compared to ‘non-ABC’
adherent management.47–50 The ABC pathway was tested in a cluster
randomized trial showing improved clinical outcomes with an ABC
pathway management based on an interactive App that included risk
assessments, patient decision aids, educational materials and dynamic
tracking of risk (mAFA-II trial20; presented as Late Breaking Science
at the ESC congress, September 2019).
Ablation
Clinical outcomes
A number of publications have described AF CA outcomes and im-
pact on prognosis. Probably the most eagerly awaited was the
CABANA study.51 This multicentre study randomized 2204 patients
to CA or drug therapy. As designed, intention to treat, the study was
neutral for CA impacting on the primary composite endpoint of
death, disabling stroke, serious bleeding, or cardiac arrest. This type
of study is incredibly difficult to recruit for because the clinicians
most likely to recruit are seeing a patient referred for a CA, so even if
A = Avoid stroke/Ancoagulaon
B = Beer symptom management
C = Comorbidies and cardiovascular risk factor 
opmisaon
1. IDENTIFY LOW-RISK PATIENTS CHA2DS2-VASc 0(m), 1(f) where no 
anthromboc therapy is recommended
2. OFFER STROKE PREVENTION if ≥1 non-sex stroke risk factor;
Assess bleeding risk, address modiﬁable bleeding risk factors
3. CHOOSE OAC (a NOAC or VKA with well-managed TTR)
1. Assess symptoms, QoL and paent’s preferences
2. Opmize rate control
3. Consider a rhythm control strategy (Cardioversion, AADs, 
Ablaon) 
Lifestyle changes (obesity reducon, regular exercise and 
reducon of alcohol use, etc.) 
Comorbidies and CV risk factors
(HTN, HF, DM, CAD, OSA, etc.) 
Secondary care
Non-Cardiologists; Cardiologists (Non-AF vs AF)
Patients with 
AFPrimary Care
Awareness and improved 
detecon of atrial 
ﬁbrillaon; allowing early 
intervenon
The ABC pathway 
for holisc integrated 
management of AF paents
Figure 2 Managing atrial fibrillation–Easy as ABC.
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..they are prepared to enter the study, the cross-over rate is likely to
be high from drug to ablation, as it was in this study (27.5%). When
analysing by treatment, there was a prognostic benefit, but this sub-
verts the principle of randomization and increases bias.
The cerebral micro-emboli associated with AF CA do not appear
to have much impact and CA itself may improve cognitive impair-
ment as in 308 patients studied and followed for 1 year.52
Most electrophysiologists continue to tell patients that the pri-
mary goal of AF ablation is quality of life (QOL). The first random-
ized controlled trials (RCT) of AF CA vs drugs to examine QOL
as the primary endpoint was published in 2019 and favoured
CA.53 While this was a small study, 155 patients, it does open the
way for double-blind RCTs of AF CA with QOL as the primary
outcome.
The use of cryoablation for AF has accumulated more evidence
this year: it is faster than RF CA,54 associated with lower risk of peri-
cardial effusion,55,56 and has superior outcomes54,55 regardless of
centre volume.57
Several large registries have published this year. The Swedish regis-
try reveals CA procedure complications and death were low and
that AF, ventricular tachycardia (VT), and premature ventricular com-
plex (PVC) CA numbers increased with AF having the highest repeat
procedure rate (41%).58 A European registry demonstrated that cry-
oablation is as effective for female patients but is associated with
higher complication rates.59 The Danish registry confirmed that suc-
cess rates for AFL ablation were 90% but that AF is a common pres-
entation (13%) within 2 years after.60 The German Helios registry
showed that pericardial effusion rates were 0.9% in 21 141 AF CA,
and was more likely in low volume centres, but only if RF was used
rather than cryo.55
CA of VF storm after myocardial infarction was reported in a mul-
ticentre study of 110 patients.61 In-hospital mortality (27%) and 2-
year follow-up mortality (36%) were high and associated with the
time taken to perform CA.
A retrospective study of 110 patients demonstrated CA of recur-
rent VT in patients with arrhythmogenic ventricular cardiomyopathy
is no more effective than drugs but is more likely to be successful if
both epicardial and endocardial approaches are used.62
Newmapping technologies
It is recognized that the primary reasons for failure of CA in complex
arrhythmia are a lack of understanding of the mechanism. There con-
tinues to be huge effort to solve this. This year ripple mapping has
been used successfully used in persistent AF (18 months 53% vs. 39%
conventional),64 atrial tachycardia,65 and VT in arrhythmogenic right
ventricular cardiomyopathy (ARVC).66 Non-contact mapping is
returning to clinical practice with an observational trial showed good
outcomes for persistent AF CA at 12 months (59%).67 The STAR
mapping system (Figure 3), presented its feasibility clinical trial of 35
patients showing freedom from AF after persistent AF CA guided by
STAR of 80% at 18 months.68 It remains to be seen whether any of
these make it to widespread clinical use.
Energy sources
High power short-duration RF may make point-by-point AF CA
faster and, at least so far, not being associated with worse
Figure 3 Ai- STAR map in an anterior-posterior view that shows an ESA (highlighted by the number 1) mapped to the anterior wall at the base of
the LA appendage. Aii- Ablation here as demonstrated on a CARTO map in an anterior-posterior view resulted in Aiii- AF cycle length slowing from
152ms to 193ms as measured from the LA appendage electrograms. Further cluster lesions at this ESA also intermittently organised CS activation.
Bi- STAR map in a tilted posterior-anterior view that shows a further ESA (highlighted by the number 2) mapped to the posterior-inferior wall. Bii-
Ablation here as shown on the CARTO maps in a similar view resulted in Biii- AF termination to AT as shown on the intracardiac electrograms. The
AT was mapped to a mitral isthmus dependent flutter which was successfully ablated to sinus rhythm.
4 A.J. Camm et al.
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..outcomes.63 Electroporation is also showing promise as a novel en-
ergy source that is highly effective with low complication rates.69 The
use of radiotherapy to treat intractable VT is an exciting innovation,
showing promising results in a small prospective study of 19
patients.70
Guidelines and consensus statements
A number of guidelines have been published this year and while these
are useful reviews of the literature, the temptation to accept them as
dogma has to be resisted given that they are often drive by consensus
of a well-intentioned writing group rather than hard data. CA of ven-
tricular arrhythmia (VA) guideline suggests that programmed elec-
trical stimulation may come back into fashion as a method for
prognostic prediction, this time in patients with frequent PVCs and
structural heart disease, and also recommends use of ICE for VA ab-
lation although much of the world does not use ICE without any ap-
parent compromise to their outcomes.71 The sex differences in
arrhythmia consensus highlighted that although outcomes may be dif-
ferent, this should not influence provision of CA for females.72
Ventricular arrhythmias
Arrhythmogenic cardiomyopathy
This has been an exciting year in arrhythmogenic cardiomyopathy
(ACM). There are major publications to be aware of. The first is the
Heart Rhythm Society Consensus Document on Arrhythmogenic
Cardiomyopathy.73 This document, which was led by McKenna and
Towbin redefines ACM as a condition that presents with symptomat-
ic and/or asymptomatic arrhythmias in association with some degree
of cardiac dysfunction. This ‘big tent’ approach includes classic ARVC,
the more recently described arrhythmogenic left ventricular
cardiomyopathy, as well as other subgroups of patients. Included
within ACM are sarcoidosis, Chagas disease, myocarditis, and a large
number of inherited cardiomyopathies. This is a comprehensive and
provocative article that is important to be aware of. One of the writ-
ing groups goals was to encourage having patients present with
arrhythmias and a cardiomyopathy to a specialized centre that per-
form comprehensive evaluation, arrange for genetic testing, and de-
termine a patient’s arrhythmic risk and need for an ICD.74
Another important publication was authored by Cadrin-Tourigny
et al.74 Through the combined efforts of five international ARVC
registries, an ARVC risk calculator was developed to help estimate
arrhythmic risk and inform decisions regarding ICD implantation
(www.ARVCrisk.com). More than 500 ARVC patients from five
registries in North America and Europe were enrolled. During 5
years of follow-up, 28% experienced sustained VT, sudden death, or
received an appropriate ICD therapy. A prediction model to estimate
annual arrhythmic risk was developed (Figure 4). The variables at
baseline included in the model are recent syncope, age, gender, non-
sustained VT, the number of PVCs in 24 h, and right ventricular ejec-
tion fraction. And a final paper by Chatterjee et al.75 investigated the
diagnostic value of an anti-Desmoglein-2 antibody in diagnosing
ARVC. An antibody to DSG-2 was identified in 12/12 and 25/25
ARVC cohorts and 7/8 borderline subjects. The antibody was absent
in 11/12 and 20/20 control cohorts. The authors concluded that anti-
DSG-2 antibodies are a sensitive and specific marker for ARVC.
Before this test can be used clinically, it will need to be tested in more
control populations including those with cardiac sarcoidosis.
Cardiac arrest
Sondergaard et al.76 examined the use of bystander CPR among
patients who experience out of hospital cardiac arrest in Denmark.
More than three-fourths of cardiac arrests occurred in residential
Figure 4 Prediction of sustained ventricular arrhythmia in arrhythmogenic right ventricular dysplasia/cardiomyopathy. ARVC, arrhythmogenic
right ventricular dysplasia/cardiomyopathy; inv., inversion; PVC, premature ventricular complex; RVEF, right ventricular ejection fraction; VT, ven-
tricular tachycardia.74
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..locations. Bystander CPR increased between 2001 and 2004 from
36% to 84% in public locations and from 16% to 61% in residential
locations. Not surprisingly, the increased use of CPR resulted in an
increased 30-day survival from 6% to 25% for arrests in public loca-
tions and from 3% to 10% in residential locations.
Cardiac devices
What is the evidence behind current guideline recommendations
for primary prevention ICD implantation in our present day and
age? Can patient populations, background therapies and treat-
ment algorithms, particular in heart failure, underlying trials con-
ducted well over a decade ago be extrapolated to current daily
clinical practice? (Figure 5)77 According to a large analysis from
the French-British-Swedish-Czech CRT Network, death due to
progressive heart failure remains the leading cause of death for
the majority of patients.78 Moreover, increasing evidence indicate
left ventricular (LV) remodelling as a main driver or arrhythmo-
genic events leading to sudden cardiac death (SCD), which may
be reduced by modalities aimed at preventing (or even reversing)
these processes, i.e. neurohormonal blockade and cardiac
resynchronization therapy (CRT).79 These concepts and findings
call into question the validity of the available randomized clinical
trial evidence underlying current recommendations for primary
prevention ICD implantation in heart failure patients. On a con-
ceptual level, they additionally raise the question if trials should
generally come with a ‘due date’ after which they would require
re-validation. On the flipside, however, device therapies have
advanced over the last decades, including better algorithms to
detect ventricular arrhythmias and to prevent inadequate shocks,
as well as the development of extravascular systems such as the
S-ICD and the extravascular (EV-) ICD.80 Indeed, even entirely
leadless CRT systems appear to be feasible.81 If proven safe and
effective in the (ongoing) large RCTs, these novel modalities will
come with a substantially reduced system-related morbidity,
which may again tip the scale towards device-based SCD preven-
tion. Indeed, inadequate shocks, as well as infections, remain the
most devastating complications of current ICD systems, which
come along with a substantial impact on quality of life, morbidity,
and mortality.82
In addition, better means of risk prediction for SCD above and be-
yond left ventricular ejection fraction (LVEF) are desperately needed
in order to better protect those patients who need it (and prevent
those who do not from unnecessary device implantation). One such
risk prediction model for patients post-myocardial infarction with
preserved LVEF has recently been put forward using electrocardio-
graphic non-invasive risk factors (PVCs, non-sustained VT, late
potentials, prolonged QTc, increased T-wave alternans, reduced
heart rate variability, and abnormal deceleration capacity with abnor-
mal turbulence) combined with programmed ventricular stimula-
tion.83 The algorithm yielded an excellent sensitivity and negative
predictive value (arguably the most important parameter) of 100%,
as well as a specificity of 93.8%; on the downside, positive predictive
value was only 22%. Modern imaging modalities such as MRI may
Figure 5 Two-year cause-specific mortality and non-fatal vascular events for patients with cardiovascular disease according to New York Heart
Association class. Numbers and proportions are a conceptual representation of absolute and relative risk and are not strictly evidence based. Note
that for patients in New York Heart Association Class 4, interventions for sudden arrhythmic death may be ineffective or fail to lead to a meaningful
prolongation of life because the patient is likely soon to die of worsening heart failure. CRD, congestion-related death, otherwise called death due to
worsening heart failure; NFVE, non-fatal vascular event (e.g. myocardial infarction and stroke; note that events are more likely to be suddenly fatal as
heart failure progresses); Non-CVD, non-cardiovascular death; RSAD, resuscitatable sudden arrhythmic death; SVD, sudden vascular death; TSAD,
terminal (non-resucitatable) sudden arrhythmic death.78
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further yield added value in identifying patients at increased risk of
ventricular arrhythmias who may benefit from ICD implantation.84
Similar algorithms are being developed also for rarer disease entities
such as arrhythmogenic right ventricular cardiomyopathy (ARVC).74
If proven positive in randomized clinical outcome trials, these con-
cepts may move the field closer to venturing beyond the current
(suboptimal) standard of LVEF for risk stratification. Until such out-
come trials are available, however, it may be prudent to stick to the
currently available evidence and guideline recommendations; at the
same time, recruitment into ongoing trials is encouraged in order to
accelerate the generation of high-level evidence which may potential-
ly alter current clinical practice.
Cardiac resynchronization therapy remains an important treat-
ment modality for heart failure patients to induce reverse LV remod-
elling and to improve morbidity and mortality. However, the rate of
so-called ‘non-responders’ remains in the order of 20–30%, depend-
ing on definitions and cut-offs.85 The MORE-CRT MPP trial investi-
gated the effect of stimulating the LV from two sites instead of one to
reduce the number of non-responders.86 Five hundred and forty-
four patients classified as non-responders (defined as an LV end-
systolic volume reduction by <15%) 6 months after CRT implant-
ation were randomized to receive the ‘Multipoint’TM algorithm
turned on (MPP ON) or off (standard of care group). While the con-
version rate to ‘responders’ was no different between the two
groups (31.8% vs. 33.8%) patients in the MPP group programmed to
a wide electrode distance were significantly more likely to convert to
responders than those programmed to other vector combinations
(45.6% vs. 26.2%, P= 0.006).86 Although interesting and biologically
plausible, these findings have to be viewed as hypothesis-generating
in view of the negative primary endpoint.
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